Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Jun 30, 2013
Filed with the SEC on Aug 2, 2013 and accepted by EDGAR at Aug 2, 2013, 20:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-04-01 to 2013-06-30 | $310.8m | us-gaap:Revenues |
| Revenue | 6 months2013-01-01 to 2013-06-30 | $639.1m | us-gaap:Revenues |
| Cost of revenue | 3 months2013-04-01 to 2013-06-30 | $24.7m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2013-01-01 to 2013-06-30 | $55.6m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2013-04-01 to 2013-06-30 | $222.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2013-01-01 to 2013-06-30 | $440.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2013-04-01 to 2013-06-30 | $106.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2013-01-01 to 2013-06-30 | $199.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2013-04-01 to 2013-06-30 | −$56.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2013-01-01 to 2013-06-30 | −$495.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2013-04-01 to 2013-06-30 | −$1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2013-01-01 to 2013-06-30 | −$132.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-04-01 to 2013-06-30 | −$57.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2013-01-01 to 2013-06-30 | −$365.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-04-01 to 2013-06-30 | −$0.26 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2013-01-01 to 2013-06-30 | −$1.67 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-04-01 to 2013-06-30 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2013-01-01 to 2013-06-30 | −$1.67 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2013-04-01 to 2013-06-30 | 222,053,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2013-01-01 to 2013-06-30 | 218,795,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2013-01-01 to 2013-06-30 | −$66.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2013-01-01 to 2013-06-30 | $18.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-06-30 | $531.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-06-30 | $1.72bn | us-gaap:AssetsCurrent |
| Total assets | At period end2013-06-30 | $2.58bn | us-gaap:Assets |
| Current liabilities | At period end2013-06-30 | $381.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-06-30 | $1.04bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-06-30 | $1.32bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-13-000038. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.